Clinical Trial Update: A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update for EPI-326 in EGFR-mutant non-small cell lung cancer and head and neck squamous cell carcinoma; the study is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• EPI-326

Snippet

Sponsor: EpiBiologics | Conditions: Epidermal Growth Factor, Epidermal Growth Factor Receptor | Phase 1 | Status: RECRUITING